Loading company
Braveheart Bio, Inc.
BRVE · Nasdaq · ·
$22.38+6.0%Sep 29 close
- 1M
- -18.5%
BRVE · Nasdaq · ·
$22.38+6.0%Sep 29 close
From the company’s own 8-K filing.
Braveheart Bio, Inc. has no earnings call transcript available.
“Our clinical programs continue to advance, and our IPO this summer has provided a strong financial foundation to advance the development of our global Phase 3 programs and evaluate the potential of BHB-1893 as the preferred treatment option in two indications,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Braveheart Bio is a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. Braveheart Bio’s lead product candidate, BHB-1893, is a next-generation oral small-molecule cardiac myosin inhibitor (CMI) being developed for the treatment of obstructive HCM (oHCM) and non-obstructive HCM (nHCM). Braveheart Bio is aiming to address the limitations of currently available CMIs by designing BHB-1893 for rapid onset, consistent depth of response, preservation of systolic function, prompt reversibility, and a straightforward approach to titration and monitoring.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Braveheart Bio, Inc.’s Item 2.02 8-K filed September 8, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.